Bright Minds Biosciences Comments on Recent Trading Activity
18 Agosto 2022 - 4:33PM
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”)
(Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on
developing novel drugs for targeted treatment of neuropsychiatric
disorders, epilepsy and pain, is issuing this news release in
response to a request by the Investment Industry Regulatory
Organization of Canada (“IIROC”) to comment on recent trading
activity of its stock.
The Company is not aware of any material,
undisclosed corporate developments and has no material change in
its business or affairs that has not been publicly disclosed that
would account for the recent increase in volume or price. In
accordance with applicable disclosure requirements, the Company
will advise the market of material changes, if any when they
occur.
About Bright Minds Bright Minds
is focused on developing novel transformative treatments for
neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a
portfolio of next-generation serotonin agonists designed to target
neurocircuit abnormalities that are responsible for difficult to
treat disorders such as resistant epilepsy, treatment resistant
depression, PTSD, and pain. The Company leverages its world-class
scientific and drug development expertise to bring forward the next
generation of safe and efficacious drugs. Bright Minds’ drugs have
been designed to potentially retain the powerful therapeutic
aspects of psychedelic and other serotonergic compounds, while
minimizing the side effects, thereby creating superior drugs to
first-generation compounds, such as psilocybin.
Investor Contacts: Ian
McDonaldCEO and DirectorE: ian@brightmindsbio.comT:
647-407-2515
Lisa Wilson E: lwilson@insitecony.com T:
917-543-9932
Neither Canadian Securities Exchange nor
its Regulation Services Provider (as that term is defined in the
policies of the Canadian Securities Exchange) accepts
responsibility for the adequacy or accuracy of this
release. This
news release may contain assumptions, estimates, and other
forward-looking statements regarding future events. Such
forward-looking statements involve inherent risks and uncertainties
and are subject to factors, many of which are beyond the Company's
control that may cause actual results or performance to differ
materially from those currently anticipated in such
statements.
Bright Minds Biosciences (NASDAQ:DRUG)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Bright Minds Biosciences (NASDAQ:DRUG)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024